Consumer Protection

Injectafer Dangerous Side Effects Investigation

Posted on

Migliaccio & Rathod LLP is currently investigating the pharmaceutical manufacturers of the widely used iron-deficiency anemia drug, Injectafer. Injectafer has been used to rapidly correct anemia, however conclusive to various recent clinical trials, it has been directly linked to Severe Hypophosphatemia as well as weakened bone density. Hypophosphatemia is a dangerous, potentially fatal, phosphorous deficiency […]

Product Defect

Metformin Carcinogenic Contaminants Investigation

Posted on

Migliaccio & Rathod LLP is currently investigating manufacturers of the widely used diabetes drug metformin, known by the common brand names Glucofage, Riomet, and Glumetza, for product contamination. Online pharmacy Valisure tested various metformin batches for impurities containing N-nitrosodimethylamine, or NDMA, a probable human carcinogen, and found sixteen contaminated batches. One batch contained sixteen times […]

Product Defect

Ranitidine Carcinogenic Contaminants Investigation

Posted on

Migliaccio & Rathod LLP is currently investigating manufacturers of the prescription and over-the-counter heartburn medication ranitidine, known by the brand name Zantac. The U.S. Food and Drug Administration (FDA) recently requested manufacturers pull the drug from the market, citing an ongoing investigation that found many ranitidine samples contained hazardous levels of the contaminant NDMA, a […]

Product Defect

Valsartan Carcinogenic Contaminants Investigation

Posted on

Migliaccio & Rathod LLP has filed a class action lawsuit against certain manufacturers of Valsartan, an angiotensin II receptor blocker used to treat high blood pressure and heart failure. The Food and Drug Administration issued a recall of Valsartan because it contained significant levels of N-nitrosodimethylamine (NDMA)—a probable human carcinogen—the long-term exposure of which increases […]